Possible Optical/Infrared Jet Emission in 4U 1543-47

We have taken optical and infrared observations during the 2002 outburst of the soft X-ray transient, 4U 1543-47. A secondary maximum occurs in the lightcurves during the outburst decline. This feature is much stronger at infrared wavelengths than optical. We have applied single blackbody, multicolor blackbody and broken-power law models to the optical/infrared spectral energy distribution of the secondary maximum and find that the broken power-law provides the best fit. We therefore conclude that the secondary maximum emission originates from a jet. We also show the most recent lightcurves of the 2002/2003 outburst of GX 339-4 in which a secondary maximum appears. This leads us to the conclusion that secondary maxima may be a common occurrence in soft X-ray transients during outburst decline which appear after the object transitions into the low-hard state. Infrared observations of such phenomena will give reliable triggers for multiwavelength observations, allowing us to greatly improve our knowledge of jet formation and behavior, and how this relates to the accretion geometry.Comment: 4 pages, to appear in ``X-Ray Timing 2003: Rossi and Beyond'' conference proceedings, references now visibl

THE DAIRY INDUSTRY IN TRANSITION

Livestock Production/Industries,

A FRAMEWORK FOR EVALUATING THE ECONOMIC IMPACT OF CLASSIFIED PRICING OF MILK

The objective of this paper is to analyze the effects of increasing, decreasing, or having no-minimum Class I differentials on regional fluid milk consumption, milk production, prices received by farmers, and the U.S. manufacturing milk price.Demand and Price Analysis,

SOME MAJOR ISSUES AFFECTING MINNESOTA'S COMPETITIVE POSITION IN UNITED STATES AND WORLD DAIRY MARKETS

Livestock Production/Industries,

RESTRUCTURING CLASS I PRICES -- SURPLUS MARKET VIEWPOINTS

Marketing,

Assessing the impact of health technology assessment in the Netherlands

Copyright © Cambridge University Press 2008Objectives: Investments in health research should lead to improvements in health and health care. This is also the remit of the main HTA program in the Netherlands. The aims of this study were to assess whether the results of this program have led to such improvements and to analyze how best to assess the impact from health research.Methods: We assessed the impact of individual HTA projects by adapting the "payback framework" developed in the United Kingdom. We conducted dossier reviews and sent a survey to principal investigators of forty-three projects awarded between 2000 and 2003. We then provided an overview of documented output and outcome that was assessed by ten HTA experts using a scoring method. Finally, we conducted five case studies using information from additional dossier review and semistructured key informant interviews.Results: The findings confirm that the payback framework is a useful approach to assess the impact of HTA projects. We identified over 101 peer reviewed papers, more than twenty-five PhDs, citations of research in guidelines (six projects), and implementation of new treatment strategies (eleven projects). The case studies provided greater depth and understanding about the levels of impact that arise and why and how they have been achieved.Conclusions: It is generally too early to determine whether the HTA program led to actual changes in healthcare policy and practice. However, the results can be used as a baseline measurement for future evaluation and can help funding organizations or HTA agencies consider how to assess impact, possibly routinely. This, in turn, could help inform research strategies and justify expenditure for health research.This research is funded by ZonMw, the Netherlands organization for health research and development (project 945-15-001)

SOCIAL COST OF THE DAIRY PRICE SUPPORT PROGRAM

Agricultural and Food Policy,

CAN THE UNITED STATES COMPETE WITH DAIRY EXPORTING NATIONS?

International Relations/Trade,

Reforming the cancer drug fund focus on drugs that might be shown to be cost effective

The Cancer Drug Fund was originally conceived as a temporary measure, until value based pricing for drugs was introduced, to give NHS cancer patients access to drugs not approved by NICE. Spending on these drugs rose from less than the £50m (€63m; $79m) budgeted for the first year in 2010-11 to well over £200m in 2013-14, and the budget for the scheme—now extended for a further two years—will reach £280m by 2016.1 The recent changes to the fund recognise the impossibility, within any sensible budget limit, of providing all the new cancer drugs that offer possible benefit to patients. More radical changes are needed to the working of the fund, given the failure to introduce value based pricing, so that it deals with the underlying problem of inadequate information on the effectiveness and cost effectiveness of new cancer drugs when used in the NHS